Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Poirier

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Cell|December 18, 2020
TMEM41B Is a Pan-flavivirus Host FactorH-Heinrich Hoffmann, William M Schneider, Kathryn Rozen-Gagnon, et al.
Science Translational Medicine|July 1, 2016
P-selectin is a nanotherapeutic delivery target in the tumor microenvironmentYosi Shamay, Moshe Elkabets, Hongyan Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer ModelsTran T Hoang, David Bauer, Aidan Ingham, et al.
Nature Communications|September 29, 2025
Magnetic imaging under high pressure with a spin-based quantum sensor integrated in a van der Waals heterostructureZ Mu, J Fraunié, A Durand, et al.
Iscience|October 29, 2021
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancerRebecca Caeser, Christopher Hulton, Emily Costa, et al.
Bioconjugate Chemistry|April 9, 2021
Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPETSai Kiran Sharma, Pierre Adumeau, Outi Keinänen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low ToxicityKathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
The Journal of Clinical Investigation|November 21, 2018
Peptide-based PET quantifies target engagement of PD-L1 therapeuticsDhiraj Kumar, Ala Lisok, Elyes Dahmane, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Cell|December 18, 2020
TMEM41B Is a Pan-flavivirus Host FactorH-Heinrich Hoffmann, William M Schneider, Kathryn Rozen-Gagnon, et al.
Science Translational Medicine|July 1, 2016
P-selectin is a nanotherapeutic delivery target in the tumor microenvironmentYosi Shamay, Moshe Elkabets, Hongyan Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer ModelsTran T Hoang, David Bauer, Aidan Ingham, et al.
Nature Communications|September 29, 2025
Magnetic imaging under high pressure with a spin-based quantum sensor integrated in a van der Waals heterostructureZ Mu, J Fraunié, A Durand, et al.
Iscience|October 29, 2021
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancerRebecca Caeser, Christopher Hulton, Emily Costa, et al.
Bioconjugate Chemistry|April 9, 2021
Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPETSai Kiran Sharma, Pierre Adumeau, Outi Keinänen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low ToxicityKathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung CancersMorana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
The Journal of Clinical Investigation|November 21, 2018
Peptide-based PET quantifies target engagement of PD-L1 therapeuticsDhiraj Kumar, Ala Lisok, Elyes Dahmane, et al.
Pageof 12